经皮冷冻消融治疗腹膜转移瘤的可行性与安全性
回顾性分析28例患者31次经皮冷冻消融治疗32个腹膜转移瘤,技术成功率100%。不良事件发生率9.7%,1年无局部进展率62.7%。消融区外新发腹膜转移常见,支持其作为综合治疗中的局部辅助手段。
要点
- 技术成功率高,不良事件发生率低,无操作相关死亡
- 术后应密切监测消融区外新发腹膜转移
- 定位为多学科综合治疗中的局部辅助治疗而非根治性治疗
核心结论
- 经皮冷冻消融治疗腹膜转移瘤技术上可行,不良事件发生率低
- 消融区外新发腹膜转移常见,中位发生时间为4.5个月
- 冷冻消融应作为多学科综合治疗中的局部辅助手段而非确定性治疗
研究设计与样本
- 回顾性研究,单中心机构消融数据库,时间范围为2011年1月至2026年1月
- 纳入28例患者(57%女性,平均年龄67.7±13.8岁),共31次冷冻消融治疗32个腹膜转移灶
- 不良事件按介入放射学会标准分级
- 采用区间删失Turnbull估计法评估无局部进展,敏感性分析将死亡作为竞争事件
诊断标准与关键数值
- 技术成功定义:31次操作均达技术成功(100%)
- 22次操作(71%)进行肠管水分离
- 不良事件发生率:3次操作后发生(9.7%),其中1例严重不良事件(3.2%),无操作相关死亡
- 患者水平局部控制失败:28例中10例在首次冷冻消融后发生
- 365天无局部进展率:62.7%(95%CI, 37.7%-100%)
临床应用与阅片要点
- 术前应评估肠管与病灶关系,必要时行水分离以保护肠管
- 术后随访应关注消融区外新发腹膜病灶,而非仅评估局部控制
- 该技术适用于筛选后的患者,应纳入多学科综合治疗框架使用
局限性
- 单中心回顾性研究设计
- 样本量较小(28例患者、31次操作)
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the feasibility, safety, and local-control outcomes of percutaneous cryoablation for treatment of peritoneal metastases.
METHODS: Retrospective review of an institutional ablation database identified 28 patients (57% female, mean age 67.7 ± 13.8 years) who underwent 31 cryoablation procedures for treatment of 32 peritoneal metastases between January 2011 and January 2026. Patient characteristics, procedural details, adverse events, and oncologic outcomes were recorded. Adverse events were classified according to Society of Interventional Radiology criteria. Freedom from local progression was estimated at the patient level using an interval-censored Turnbull estimator, with sensitivity analysis estimating cumulative incidence of detected local progression with death considered as a competing event.
RESULTS: Technical success was achieved in all 31 procedures. Hydrodisplacement of bowel was performed in 22 procedures (71%). Adverse events occurred after 3 procedures (9.7%), including one major adverse event (3.2%). There was no procedure-related mortality. Patient-level local control failure after the index cryoablation procedure occurred in 10 of 28 patients. Estimated freedom from local progression was 62.7% (95% CI, 37.7%-100%) at 365 days. In competing-risk analysis, the cumulative incidence of detected local progression before death was 28.6% (95% CI, 15.9%-51.3%) at 365 days. New peritoneal metastases outside the ablation zone developed after 21 of 31 sessions (67.7%) at a median of 4.5 months.
CONCLUSION: In selected patients, percutaneous cryoablation of peritoneal metastases was technically feasible with infrequent adverse events. New peritoneal disease was common, supporting a role for cryoablation as an adjunctive focal therapy within a multimodality treatment paradigm rather than as a definitive therapy.
引用
- Rogers, Hibbert, Larson, et al. Feasibility and safety of percutaneous cryoablation for treatment of peritoneal metastases. Abdom Radiol (NY). 2026. PMID: 42730776. doi:10.1007/s00261-026-05784-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。